Guardant Health’s Liquid Biopsy Test Wins FDA Nod for Pfizer-Arvinas Breast Cancer Drug
Event summary
- Guardant Health’s Guardant360® CDx liquid biopsy test received FDA approval as a companion diagnostic for Pfizer and Arvinas’ VEPPANU (vepdegestrant) for ER+/HER2- advanced breast cancer with ESR1 mutations.
- VEPPANU, a PROTAC therapy, targets ESR1 mutations, a common resistance mechanism to endocrine therapy in advanced breast cancer.
- This is the third ESR1 companion diagnostic approval for Guardant360 CDx and the 26th companion diagnostic indication across multiple tumor types.
- The approval expands Guardant Health’s coverage by Medicare and commercial payers, representing over 300 million covered lives.
The big picture
This FDA approval underscores the growing role of liquid biopsy tests in precision oncology, enabling non-invasive identification of genetic mutations that guide targeted therapies. Guardant Health’s expanding portfolio of companion diagnostics strengthens its position in the market, while the collaboration with Pfizer and Arvinas highlights the strategic importance of partnerships in advancing cancer treatment. The approval also reinforces the trend toward personalized medicine, where diagnostic tools play a crucial role in treatment selection.
What we're watching
- Market Expansion
- How Guardant Health will leverage this approval to expand its market share in precision oncology and liquid biopsy testing.
- Clinical Utility
- Whether the increased adoption of Guardant360 CDx will drive more personalized treatment options for advanced breast cancer patients.
- Regulatory Momentum
- The pace at which Guardant Health can secure additional companion diagnostic approvals for other cancer therapies.
Related topics